Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis
Mariko KobayashiShinji EndoYukako HamanoMamiko ImanishiDaisuke AkutsuAkinori SugayaDaisuke OchiToshikazu MoriwakiIchinosuke Hyodo
Author information
JOURNALS OPEN ACCESS

2016 Volume 55 Issue 2 Pages 127-130

Details
Abstract

Combination chemotherapy of mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin) plus panitumumab, a fully human monoclonal antibody against epidermal growth factor receptor (EGFR), is one of the standard treatments for metastatic colorectal cancer (mCRC) without KRAS mutation. A few reports suggested no need of dose adjustment of cetuximab, a similar chimeric anti-EGFR antibody, in patients with renal impairment. However, panitumumab combined with cytotoxic drugs for hemodialysis patients has not been reported. We herein report a case of a hemodialysis mCRC patient successfully treated with mFOLFOX6 and panitumumab combination therapy.

Information related to the author
© 2016 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top